Bristol Myers Squibb (BMY) Return on Equity (2016 - 2026)

Bristol Myers Squibb has reported Return on Equity over the past 17 years, most recently at 0.0% for Q1 2026.

Quarterly Return on Equity changed 0.0% to 0.0% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.0% through Mar 2026, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 2.0% up from the prior year.
Return on Equity was 0.0% for Q1 2026 at Bristol Myers Squibb, down from 0.0% in the prior quarter.
Over five years, Return on Equity peaked at 0.29% in Q2 2025 and troughed at 0.25% in Q3 2024.
The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.01%.
Year-over-year, Return on Equity fell -23bps in 2024 and then rose 29bps in 2025.
A 5-year view of Return on Equity shows it stood at 0.06% in 2022, then surged by 110bps to 0.01% in 2023, then tumbled by -295bps to 0.01% in 2024, then surged by 132bps to 0.0% in 2025, then decreased by -1bps to 0.0% in 2026.
Per Business Quant, the three most recent readings for BMY's Return on Equity are 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison